Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring.

Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring.

Item
http://www.wikidata.org/entity/Q36440866
Clozapine Monitoring in Clinical Practice: Beyond the Mandatory RequirementQuo Vadis Clozapine? A Bibliometric Study of 45 Years of Research in International Context.Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in IcelandPharmacotherapeutic strategies for pediatric bipolar disorder.Haematological toxicity of clozapine and some other drugs used in psychiatry.Successful clozapine continuation during chemotherapy for the treatment of malignancy: a case report.Association between CYP1A2 gene single nucleotide polymorphisms and clinical responses to clozapine in patients with treatment-resistant schizophrenia.Outcome definitions and clinical predictors influence pharmacogenetic associations between HTR3A gene polymorphisms and response to clozapine in patients with schizophrenia.Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric population.Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine.[Evidence-based treatment of psychosis associated with Parkinson's disease].
P2860

Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring.

Item
http://www.wikidata.org/entity/Q36440866
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring.
@ast
Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring.
@en
type
label
Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring.
@ast
Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring.
@en
prefLabel
Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring.
@ast
Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P921
P356
P1433
P1476
Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring.
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P921